Ctry2459-H2

General Information


DRACP ID  DRACP02618

Peptide Name   Ctry2459-H2

Sequence  FLGFLHHLF

Sequence Length  9

UniProt ID  P0DMF3 

PubChem CID  Not available

Origin  Synthetic

Type  Synthetic peptide

Classification

  

Active ACP



Activity Information


Cell Line Disease Cancer Classified Activity Assay Testing Time Literature
Huh7.5.1 Adult hepatocellular carcinoma Carcinoma CC50>500 µg/ml MTT assay 48 h 1

Hemolytic Activity  Human erythrocytes: HC50=203.3 µg/ml

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available

Nature  Anticancer; Antiviral



Structure Information


PDB ID  Not available

Predicted Structure  DRACP02618

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C59H79N13O10

Absent amino acids  ACDEIKMNPQRSTVWY

Common amino acids  FL

Mass  127324

Pl  7.72

Basic residues  2

Acidic residues  0

Hydrophobic residues  6

Net charge  2

Boman Index  1532

Hydrophobicity  144.44

Aliphatic Index  130

Half Life 
  Mammalian: 1.1 hour
  Yeast: 3 min
  E.coli: 2 min

Extinction Coefficient cystines  0

Absorbance 280nm  0

Polar residues  1

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 23415044

Title  Design of histidine-rich peptides with enhanced bioavailability and inhibitory activity against hepatitis C virus

Doi 10.1016/j.biomaterials.2013.01.075

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPR_5444

DRACP is developed by Dr.Zheng's team.